Definition and Etiology

• Congenital Nephrotic Syndrome (CNS) is clinically defined as the presentation of heavy proteinuria, profound hypoalbuminemia, and generalized edema manifesting at birth or within the first 3 months of life.
• It is a rare but severe glomerular disorder that carries a significantly poorer prognosis compared to childhood-onset idiopathic nephrotic syndrome.
• The etiology of CNS is heterogeneous and broadly classified into primary (genetic) causes and secondary (acquired) causes.
• Primary CNS is predominantly monogenic, arising from mutations in critical structural and functional proteins of the glomerular slit diaphragm and basement membrane, which account for over 80-90% of cases.
• Secondary CNS is caused by in utero or perinatal systemic insults, most commonly congenital infections.

Classification and Key Etiological Variations

Pathophysiology

• The glomerular filtration barrier (GFB) consists of the fenestrated endothelium, the glomerular basement membrane (GBM), and the specialized podocyte foot processes.
• Under normal physiological conditions, the GFB restricts the transglomerular passage of macromolecules based on size, charge, and steric configuration.
• The slit diaphragm acts as the primary molecular sieve; its structure is maintained by transmembrane homophilic interactions of nephrin (NPHS1) which recruits and interacts with podocin (NPHS2) in lipid-raft microdomains.
• Mutations in NPHS1 (such as the Fin-major and Fin-minor truncation variants) or NPHS2 cause misfolding and endoplasmic reticulum-retention of these critical proteins, leading to an absent slit diaphragm and complete loss of filtration selectivity.
• This structural disruption triggers diffuse podocyte foot process effacement, massive urinary loss of albumin, and a subsequent decrease in plasma oncotic pressure.
• Urinary losses are not restricted to albumin: loss of thyroid-binding globulin causes hypothyroidism; loss of immunoglobulins (IgG) and complement factors (C3, C5, factors B/D) impairs opsonization and predisposes to severe bacterial infections; and loss of antithrombin III induces a highly hypercoagulable state.

Clinical Features

• Antenatal and Perinatal Findings: Maternal history is frequently marked by elevated maternal and amniotic fluid $\alpha$-fetoprotein (AFP) levels. Infants are often born prematurely, displaying meconium-stained amniotic fluid and characteristically enlarged placentas exceeding 25% of the infant's birth weight.
• Renal Manifestations: Severe generalized edema (anasarca), marked abdominal distension, ascites, and pleural effusions typically become apparent in the first few weeks of life. Urine output is initially variable, but oliguria quickly supervenes.
• Systemic Complications:
  • Hypothyroidism: Clinically manifests as poor activity and sluggishness due to urinary thyroxine-binding globulin loss.
  • Severe Infections: Increased vulnerability to life-threatening bacterial infections, including pneumococcal sepsis, spontaneous bacterial peritonitis, and cellulitis.
  • Thromboembolic Events: High risk of deep venous thrombosis, renal vein thrombosis, and cerebral sagittal sinus thrombosis secondary to hemoconcentration and loss of anticoagulant factors.
  • Severe Growth Faltering: Chronic protein malnutrition and high metabolic demands lead to progressive muscle wasting and physical growth retardation.

Diagnostic Evaluation

• Urinalysis and Biochemistry: Confirms massive proteinuria (urinary protein excretion $>20 \text{ g/L}$ or spot urine protein-to-creatinine ratio $>2.0$) and severe hypoalbuminemia (serum albumin $<10 \text{ g/L}$ at birth). Profound hyperlipidemia (cholesterol $>200 \text{ mg/dL}$) is characteristic.
• Endocrine and Coagulation Assays: Show low serum thyroxine ($T_4$) with elevated thyroid-stimulating hormone (TSH), decreased IgG levels, and reduced antithrombin III levels.
• Infection Screening: Patient and maternal serology (TORCH, syphilis, HIV, hepatitis B/C PCR) must be obtained immediately to exclude treatable secondary infectious causes of CNS.
• Genetic Testing (First-Line): Next-generation sequencing (NGS) targeted panels covering NPHS1, NPHS2, WT1, LAMB2, and PLCE1 are the gold standard and identify a molecular cause in over 80% of cases. Genetic confirmation establishes a definitive diagnosis, guides prognosis, and obviates the need for invasive kidney biopsies.
• Kidney Biopsy: Indicated only when rapid genetic diagnostics are unavailable or negative. Histopathology demonstrates variable combinations of mesangial expansion, FSGS, or diffuse mesangial sclerosis (DMS), alongside proximal tubular microcystic dilation.

Diagnostic Algorithm

graph TD;
    A[Neonate/Infant < 3 months with severe Edema & Proteinuria] --> B[Urinalysis, Serum Albumin, LFTs & Renal Function];
    B --> C[Perform Maternal & Patient Serology for CMV, Syphilis, Toxoplasmosis, HIV, HBV/HCV];
    C --> D{Serology Positive?};
    D -- Yes --> E[Diagnose Secondary CNS -> Administer Specific Antimicrobial Therapy];
    D -- No --> F[Perform Next-Generation Sequencing NGS Gene Panel];
    F --> G{Genetic Mutation Identified?};
    G -- Yes --> H[Confirm Primary Genetic CNS -> Avoid Immunosuppression];
    H --> I[Monitor WT1 cases with Renal USG every 3 months for Wilms Tumor];
    G -- No --> J[Consider Kidney Biopsy -> Rule out atypical DMS/FSGS/MCD -> Supportively Manage];

Management

Medical and Supportive Therapy

• Immunosuppression Avoidance: Standard glucocorticoids and other immunosuppressive agents are completely ineffective in primary genetic CNS. They must be strictly avoided as they fail to induce remission and exponentially increase the risk of fatal infections.
• Nutritional Support: High-energy ($110\text{–}120 \text{ Cal/kg/day}$) and high-protein ($3\text{–}3.5 \text{ g/kg/day}$) enteral or parenteral feeding is vital to counteract urinary protein losses and achieve adequate weight gain.
• Albumin and Diuretic Infusions: Cautious use of 20% or 25% intravenous albumin infusions ($0.5\text{–}1 \text{ g/kg}$) over 2-4 hours combined with loop diuretics (furosemide) helps manage symptomatic severe anasarca and maintains intravascular volume.
• Endocrine and Anti-infective Care: Daily oral L-thyroxine substitution is mandatory, titrated to normalize TSH levels. Prophylactic antibiotics (such as alternate-day cotrimoxazole) and regular administration of intravenous immunoglobulin (IVIG) should be considered to prevent recurrent severe bacterial infections.
• Pharmacological Antiproteinuric Therapy: Renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors (e.g., Captopril), often combined with prostaglandin synthesis inhibitors (e.g., indomethacin), is used after the neonatal period to reduce glomerular perfusion pressure and diminish the severity of proteinuria.

Surgical Management and Renal Replacement Therapy

• Unilateral Nephrectomy: May be performed as an intermediate step in selected infants to significantly curtail urinary protein losses, decrease the requirement for daily albumin infusions, and improve nutritional status.
• Bilateral Nephrectomy & Dialysis: Indicated in clinically unstable infants with severe refractory nephrotic states who develop life-threatening complications (recurrent sepsis, thrombosis, extreme malnutrition). Once the child achieves a body weight of $7\text{–}10 \text{ kg}$, bilateral nephrectomy is performed, and peritoneal dialysis is initiated.
• Definitive Treatment (Kidney Transplantation): Kidney transplantation is the only curative option for genetic CNS and is typically scheduled between 1 and 3 years of age once the patient is stable and non-nephrotic. Suitable living donors are parents (who are heterozygous carriers). Recurrence of proteinuria in the graft is exceptional, only occurring in a subset of CNF patients who develop circulating anti-nephrin antibodies.

Comprehensive Treatment Strategy Flowchart

graph TD;
    A[Primary Genetic CNS Confirmed] --> B[Conservative Phase];
    B --> C[Aggressive Nutrition: Protein 3-3.5 g/kg/d, Energy 110-120 Cal/kg/d];
    B --> D[Antiproteinurics: Captopril +/- Indomethacin];
    B --> E[Supportive Care: L-Thyroxine, IVIG, Albumin Infusions + Furosemide];
    B --> F{Patient Stable with Good Growth?};
    F -- Yes --> G[Delay Nephrectomy -> Maintain Conservative Care until ESKD -> Peritoneal Dialysis];
    F -- No --> H[Unstable: Recurrent Infections, Severe Thrombosis, Anasarca];
    H --> I[Consider Unilateral Nephrectomy to reduce protein loss];
    I --> K{Fails to Stabilize?};
    K -- Yes --> L[Bilateral Nephrectomy + Dialysis once Weight is 7-10 kg];
    K -- No --> G;
    G --> M[Kidney Transplantation at 1-3 years of age];
    L --> M;